ZelquistinelZelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor positive allosteric modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan. Read from the Drugbox of the Wikipedia article Zelquistinel, revision 1372054537.

Property

Value

Formula

C15H25N3O5, 327.38 g/mol

Bioavailability

100 %

Elimination half-life

1.6 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.